Background {#Sec1}
==========

Angioimmunoblastic T-cell lymphoma (AITL) represents a distinct clinicopathologic entity among the mature T- and NK-cell neoplasms, accounting for approximately 1--2% of all non-Hodgkin lymphomas (NHLs) \[[@CR1], [@CR2]\]. AITL patients typically present with advanced stage disease, diffuse lymphadenopathy, hepatosplenomegaly, systemic symptoms, and hypergammaglobulinemia \[[@CR3]\]. The clinical course is aggressive and the disease generally carries a poor prognosis even when treated with intensive induction regimens \[[@CR3]\]. Standard first-line therapy mostly consists of anthracycline-based regimens with or without etoposide, based on the age \[[@CR2], [@CR4]--[@CR6]\]. With this approach, overall survival (OS) is a little over 30% at 5 years \[[@CR7]\]. In an attempt to improve the outcomes, autologous hematopoietic cell transplantation (auto-HCT) consolidation has been applied in this patient population \[[@CR8]--[@CR10]\]. While durable disease control can be observed typically in patients in first complete remission (CR), the outcomes of AITL subjects in partial remission (PR), and in those with refractory disease or treated with ≥ 2 prior therapy lines, following auto-HCT are less encouraging \[[@CR10]\].

Allogeneic HCT (allo-HCT) may result in a lower risk of relapse in part due to a *graft*-versus*-lymphoma* effect mediated by the alloreactive donor cells \[[@CR11]--[@CR13]\]. Several retrospective studies \[[@CR11], [@CR14]--[@CR16]\] have reported excellent disease control with low rates of relapse and a 1-year non-relapse mortality (NRM) ranging from 8 to 25% with allo-HCT in AITL patients. However, these analyses were done mainly in peripheral T-cell lymphoma (PTCL) patients with AITL as a subgroup or reported only a small number of patients with AITL (range *N* = 9--45 patients; Additional file [1](#MOESM1){ref-type="media"}: Table S1). We report here a registry analysis, evaluating the outcomes of patients with AITL undergoing allo-HCT.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

The Center for International Blood and Marrow Transplant Research (CIBMTR) is a working group of more than 500 transplantation centers worldwide that contribute detailed data on HCT to a statistical center at the Medical College of Wisconsin (MCW). Participating centers are required to report all transplantations consecutively and compliance is monitored by on-site audits. Computerized checks for discrepancies, physicians' review of submitted data, and on-site audits of participating centers ensure data quality. Observational studies conducted by the CIBMTR are performed in compliance with all applicable federal regulations pertaining to the protection of human research participants. The MCW and National Marrow Donor Program, Institutional Review Boards approved this study.

The CIBMTR collects data at two levels: transplant essential data (TED) and comprehensive report form (CRF) data. TED data includes disease type, age, gender, pre-HCT disease stage and chemotherapy-responsiveness, date of diagnosis, graft type, conditioning regimen, post-transplant disease progression and survival, development of a new malignancy, and cause of death. All CIBMTR centers contribute to TED data. More detailed disease and pre- and post-transplant clinical information is collected on a subset of registered patients selected for CRF data by a weighted randomization scheme. TED- and CRF-level data are collected pre-transplant, 100-days, and 6 months post-HCT and annually thereafter or until death. Data for the current analysis were retrieved from CIBMTR (TED and CRF) report forms.

Patients {#Sec4}
--------

Included in this analysis are adult (≥ 18 years) patients with AITL, undergoing their first allo-HCT between 2000 and 2016. Eligible donors included either HLA-identical sibling donors or unrelated donors (URD) matched at the allele-level at HLA-A, -B, -C, and -DRB1 and graft sources included peripheral blood and bone marrow. Graft-versus-host disease (GVHD) prophylaxis included both calcineurin inhibitor (CNI) and non-CNI-based regimens. Recipients of alternative donor transplantation were excluded due to small numbers (haploidentical allografts, *n* = 8; mismatched unrelated donor, *n* = 22; cord blood grafts, *n* = 21).

Definitions and study endpoints {#Sec5}
-------------------------------

The intensity of conditioning regimens was defined using consensus criteria \[[@CR17]\]. Disease response at the time of HCT was determined using the International Working Group criteria in use during the era of this analysis \[[@CR18]\].

The primary endpoint was OS; death from any cause was considered an event and surviving patients were censored at last contact. Secondary endpoints included cumulative incidence of acute GVHD, chronic GVHD, GVHD free, relapse-free survival (GRFS), NRM, progression/relapse, and progression-free survival (PFS). NRM was defined as death without evidence of lymphoma progression/relapse; relapse was considered a competing risk. Progression/relapse was defined as progressive lymphoma after HCT or lymphoma recurrence after a CR; NRM was considered a competing risk. For PFS, a patient was considered treatment failure at the time of progression/relapse or death from any cause. Patients alive without evidence of disease relapse or progression were censored at last follow-up. Acute GVHD \[[@CR19]\] and chronic GVHD \[[@CR20]\] were graded using standard criteria. Neutrophil recovery was defined as the first of three successive days with absolute neutrophil count (ANC) ≥ 500/μL after post-transplantation nadir. Platelet recovery was defined as achieving platelet counts ≥ 20,000/μL for at least 3 days, unsupported by transfusion. For neutrophil and platelet recovery, death without the event was considered a competing risk. The causes of death are reported in accordance to the methodology described previously \[[@CR21]\].

Statistical analysis {#Sec6}
--------------------

Probabilities of PFS and OS were calculated using the Kaplan--Meier estimates. Cumulative incidence of NRM, lymphoma progression/relapse, and GVHD were calculated to accommodate for competing risks. Associations among patient-, disease-, and transplantation-related variables and outcomes of interest were evaluated using Cox proportional hazards regression. A stepwise model-building approach was used to identify covariates that influenced outcomes. Covariates with a *p* \< 0.05 were considered statistically significant. The proportional hazards assumption for Cox regression was tested by adding a time-dependent covariate for each risk factor and each outcome. If a variable violated the proportional hazards assumption, it was added as a time-varying covariate. Interactions between the main effect and significant covariates were examined and none were found. Results are expressed as relative risks (RR). The center effect was examined using the random effect score test \[[@CR22]\] for OS, PFS, relapse, and NRM. The variables considered in multivariate analysis are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S2 of the supplemental appendix. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).

Results {#Sec7}
=======

Baseline characteristics {#Sec8}
------------------------

A total of 249 patients met the inclusion criteria and were included in this analysis. The baseline patient-, disease-, and transplantation-related characteristics are shown in Table [1](#Tab1){ref-type="table"}. The median patient age was 56 years (range = 21--77 years). Most of the patients were Caucasians (86%), with a male (60%) predominance. The majority had a chemosensitive disease at the time of allo-HCT (79%) and received a non-myeloablative/reduced intensity conditioning regimen (73%). Most common type of GVHD prophylaxis included CNI ± methotrexate-based regimens. The graft source used for allo-HCT was predominantly peripheral blood (97%). Pre-transplant (allo-HCT) donor/recipient cytomegalovirus status was available in 200 patients (81%) and the details are provided in Table [1](#Tab1){ref-type="table"}. There was no center effect noted on the outcomes. Median follow-up of survivors was 49 months (range, 4--170 months).Table 1Baseline patient characteristics of patients with AITL receiving first allo-HCT reported to the CIBMTR from 2000 to 2016Variable*N* = 249 (%)Median age at HCT, years (range)56 (21--77)Male gender150 (60)Race Caucasian214 (86) African American5 (2) Others^a^17 (7) Missing13 (5)Karnofsky performance score ≥ 90119 (48) \< 90113 (45) Missing17 (7)HCT-CI 046 (18) 1--253 (21) ≥ 384 (34) Not available before 200755 (22) Missing11 (4)Interval from diagnosis to HCT, months Median (range)14 (3--118)Median lines of therapy before HCT (range)3 (1--5)Remission status at HCT Complete remission108 (43) Partial remission90 (36) Chemorefractory38 (15) Untreated/unknown13 (5)History of prior autologous HCT98 (39)TBI in conditioning83 (34)ATG/alemtuzumab in conditioning^b^59 (24)Conditioning intensity^c^ Myeloablative conditioning66 (27) Non-myeloablative/RIC183 (73)Graft source Bone marrow8 (3) Peripheral blood241 (97)Donor type HLA-identical sibling140 (56) Unrelated donor 8/8109 (44)Donor/recipient CMV status Both negative72 (29) Both positive59 (24) Either donor/recipient +69 (28) Missing49 (19)Graft-versus-host disease prophylaxis Calcineurin inhibitor + MTX ± others^d^ (except MMF)119 (48) Calcineurin inhibitor + MMF ± others^d^76 (31) Calcineurin inhibitor + others (except MMF)40 (16) Others^d^10 (4) Missing4 (2)Year of HCT 2000--200647 (19) 2007--201182 (33) 2012--2016120 (48)Median follow-up of survivors (range), months49 (4--170)*ATG* antithymocyte globulin, CMV cytomegalovirus, *HCT* hematopoietic cell transplantation, *HCT-CI* HCT-Comorbidity index, *MMF* mycophenolate mofetil, *MTX* methotrexate, *TBI* total body irradiation, *RIC* reduced intensity conditioning^a^Others: 13 Asian; 3 Hispanic or Latino; 1 race unspecified, non-Hispanic^b^ATG/alemtuzumab---49 ATG alone; 10 alemtuzumab alone^c^For details, refer to Additional file [1](#MOESM1){ref-type="media"}: Table S4^d^For details, refer to Additional file [1](#MOESM1){ref-type="media"}: Table S5

Hematopoietic recovery {#Sec9}
----------------------

On univariate analysis, the cumulative incidence of neutrophil engraftment at 1-year was 97% (95% CI 94--99). The 1-year cumulative incidence of platelet recovery (Table [2](#Tab2){ref-type="table"}) was 91% (95% CI 87--94).Table 2Univariate AnalysisOutcomesN EvalProb (95% CI)Neutrophil engraftment**236** 1-year97 (94--99)% 2-year97 (94--99)%Platelet recovery**218** 1-year91 (87--94)% 2-year91 (87--95)%Acute GVHD (II-IV)**239** 180-day36 (30--42)%Acute GVHD (III-IV)**229** 180-day12 (8--17)%Chronic GVHD**230** 1-year49 (43--56)% 2-year58 (51--64)%Extensive cGVHD**230** 1-year39 (33--46)% 2-year46 (39--53)%GRFS**230** 1-year35 (29--41)% 2-year27 (21--33)%NRM**249** 1-year19 (14--24)% 2-year25 (20--31)% 4-year30 (24--36)%Progression/relapse**249** 1-year15 (11--20)% 2-year19 (15--25)% 4-year21 (16--27)%PFS**249** 1-year66 (60--72)% 2-year56 (49--62)% 4-year47 (41--54)%Overall survival**249** 1-year73 (68--79)% 2-year63 (56--69)% 4-year56 (49--63)%*GVHD* graft-versus-host disease, *Prob* probability, *CI* confidence interval, *N* number, *NRM* non-relapse mortality, *PFS* progression-free survival, *GRFS* GVHD free, relapse-free survivalProbabilities of acute GVHD, chronic GVHD, treatment-related mortality and progression/relapse were calculated using the cumulative incidence estimate. Progression-free survival and overall survival was calculated using the Kaplan-Meier product limit estimateUnivariate analysis of alternative donor sources is shown in Additional file [1](#MOESM1){ref-type="media"} Table S6

Acute and chronic GVHD {#Sec10}
----------------------

On univariate analysis, the cumulative incidence of grade II--IV acute GVHD was 36% (95% CI 30--42) and grades III--IV acute GVHD was 12% (95% CI 8--17) at day 180 (Table [2](#Tab2){ref-type="table"}). None of the tested covariates (Additional file [1](#MOESM1){ref-type="media"}: Table S2) affected the risk of the development of acute GVHD.

On univariate analysis, the cumulative incidence of chronic GVHD at 1-year (Table [2](#Tab2){ref-type="table"}) was 49% (95% CI 43--56), while the cumulative incidence of extensive chronic GVHD at 1 year (Table [2](#Tab2){ref-type="table"}) was 39% (95% CI 33--46). Multivariate analysis (Table [3](#Tab3){ref-type="table"}) showed that patients who received anti-thymocyte globulin (ATG) or alemtuzumab had a significantly lower risk of chronic GVHD (RR = 0.58, 95% CI 0.36--0.93, *p* = 0.02) relative to those who did not receive ATG/alemtuzumab.Table 3Multivariate analysis resultsNumberRR95% CI lower limit95% CI upper limit*P*-valueOverall *p* valueChronic GVHD ATG/alemtuzumab  No1741*0.02*  Yes550.580.360.93*0.02*Progression/Relapse No significant covariatesNon-relapse mortality No significant covariatesProgression-free survival Disease status  CR1081*0.03*  PR901.130.761.660.54  Chemoresistant381.731.082.77*0.02*  Missing/Untreated130.430.151.200.11Overall survival Karnofsky performance score (≤ 6 months)^a^  ≥ 90%1191*0.002*  \< 90%1133.461.746.87*0.0004*  Missing171.950.546.980.31 Karnofsky performance score (\> 6 months)^a^  ≥ 90%10610.28  \< 90%800.660.391.120.12  Missing140.730.291.860.51*GVHD* graft-versus-host disease, *CI* confidence interval, *ATG* anti-thymocyte globulin, *CR* complete remission, *PR* partial remission, *RR* relative riskVariables tested in the Multivariate analysis are listed in Additional file [1](#MOESM1){ref-type="media"} Table S2^a^6-months was chosen as cut-off based on the maximum likelihood value in the Cox model*p*-value \<0.05 is considered significant

Transplantation outcomes {#Sec11}
------------------------

On univariate analysis, the cumulative incidence of 1-year GRFS (Table [2](#Tab2){ref-type="table"}) was 35% (95% CI 29--41).

The 1-year NRM rate (Table [2](#Tab2){ref-type="table"}) was 19% (95% CI 14--24) (Fig. [1](#Fig1){ref-type="fig"}a). On multivariate analysis, there were no significant covariates affecting the risk of NRM. The cumulative incidence of progression/relapse at 4 years (Table [2](#Tab2){ref-type="table"}) was 21% (95% CI 16--27) (Fig. [1](#Fig1){ref-type="fig"}b). On multivariate analysis (Table [3](#Tab3){ref-type="table"}), none of the covariates (Additional file [1](#MOESM1){ref-type="media"}: Table S1, including chronic GVHD assessed as a time-dependent variable) significantly affected the relapse risk.Fig. 1Outcomes of patients receiving first allo-HCT for AITL. **a** Cumulative incidence of non-relapse mortality. **b** Cumulative incidence of lymphoma progression/relapse. **c** Progression-free survival. **d** Overall survival

The 4-year PFS and OS (Table [2](#Tab2){ref-type="table"}) were 47% (95% CI 41--54) (Fig. [1](#Fig1){ref-type="fig"}c) and 56% (95% CI 49--63) (Fig. [1](#Fig1){ref-type="fig"}d), respectively. On multivariate analysis (Table [3](#Tab3){ref-type="table"}), chemoresistant status at the time of allo-HCT significantly increased the risk for therapy failure (inverse of PFS) (RR = 1.73 95% CI = 1.08--2.77, *p* = 0.02), while KPS \< 90% was associated with a significantly higher risk of mortality (inverse of OS) in the first 6-months post allo-HCT (RR = 3.46 95% CI = 1.74--6.87, *p* = 0.0004).

Causes of death {#Sec12}
---------------

At last follow-up, 45% (*n* = 112) of allo-HCT recipients had died (Additional file [1](#MOESM1){ref-type="media"}: Table S3). The most common cause of death was organ failure, 20% (*n* = 22) followed by recurrent/progressive disease, 19% (*n* = 21). GVHD was the cause of death in 17% (*n* = 19) and infectious complications accounted for death in 15% (*n* = 17) of patients. The other causes of death are listed in Additional file [1](#MOESM1){ref-type="media"}: Table S3.

Impact of prior autograft and disease status {#Sec13}
--------------------------------------------

Among the 249 patients who received first allo-HCT, 98 patients (39%) had received a prior auto-HCT. Univariate analysis looking at the impact of prior auto-HCT (no prior auto-HCT vs prior auto-HCT) on the outcomes showed no significant difference in the 1-year NRM (17% \[95% CI 11--23\] vs 22% \[95% CI 14--30\], *p* = 0.33), 4-year progression/relapse (24% \[95% CI 17--31\] vs 17% \[95% CI 10--25\], *p* = 0.21), PFS (50% \[95% CI 42--59\] vs 47% \[95% CI 36--57\], *p* = 0.60), or OS (57% \[95% CI 49--65\] vs 54% \[95% CI 44--65\], *p* = 0.70) (Table [4](#Tab4){ref-type="table"}**,** Fig. [2](#Fig2){ref-type="fig"}).Table 4Comparative analysis of AITL patients who received prior auto-HCT vs no prior auto-HCTOutcomesNo prior auto-HCT (*N* = 151)Prior auto-HCT (*N* = 98)*p* value*N*Prob (95% CI)*N*Prob (95% CI)NRM**15198**0.251-year17 (11--23)%22 (14--30)%0.332-year21 (15--28)%31 (22--41)%0.083-year22 (16--29)%33 (23--43)%0.074-year26 (19--34)%36 (26--47)%0.11Progression/relapse**15198**0.691-year16 (11--22)%15 (8--22)%0.772-year22 (15--29)%16 (9--24)%0.233-year23 (16--30)%17 (10--25)%0.284-year24 (17--31)%17 (10--25)%0.21PFS**15198**0.451-year68 (60--75)%64 (54--73)%0.562-year57 (49--65)%53 (43--63)%0.533-year55 (47--64)%50 (40--61)%0.434-year50 (42--59)%47 (36--57)%0.60Overall survival**15198**0.811-year73 (65--80)%74 (65--82)%0.812-year65 (57--72)%59 (49--69)%0.433-year61 (53--69)%58 (47--68)%0.634-year57 (49--65)%54 (44--65)%0.70*Prob* probability, *CI* confidence interval, *N* number, *NRM* non-relapse mortality, *PFS* progression-free survival, *HCT* hematopoietic cell transplantationFig. 2Outcomes of AITL patients based on the receipt of prior auto-HCT vs no prior auto-HCT. **a** Cumulative incidence of non-relapse mortality. **b** Cumulative incidence of lymphoma progression/relapse. **c** Progression-free survival. **d** Overall survival

Among the 198 patients with chemosensitive disease at the time of allo-HCT, 33 patients (17%) were in CR1, while 75 patients (38%) were in CR \> 1 and 90 patients (45%) were in PR. Univariate analysis looking at the effect of remission status at allo-HCT, CR1 vs CR \> 1 vs PR vs refractory (Table [5](#Tab5){ref-type="table"}), showed a 4-year PFS of 58% vs 45% vs 47% vs 38%, respectively, and a 4-year OS of 70% vs 54% vs 50% vs 52%, respectively. Among patients with chemorefractory AITL, the 1-year NRM was 24%, while the 4-year progression/relapse, PFS, and OS in patients with refractory AITL were 32%, 38%, and 52%, respectively. Figure [3](#Fig3){ref-type="fig"} shows the disease outcomes for AITL patients based on the remission status at allo-HCT (CR vs PR vs chemoresistant).Table 5Comparative analysis of AITL patients based on the remission status at the time of allo-HCTCR1 (*N* = 33)CR \> 1 (*N* = 75)PR (*N* = 90)Refractory (*N* = 38)Outcomes*N*Prob (95% CI)*N*Prob (95% CI)*N*Prob (95% CI)*N*Prob (95% CI)NRM**33759038**1-year6 (1--17)%20 (12--30)%20 (13--29)%24 (12--38)%2-year13 (4--26)%29 (19--40)%25 (17--35)%30 (16--45)%3-year17 (6--32)%31 (21--43)%25 (17--35)%30 (16--45)%4-year17 (6--32)%36 (25--49)%33 (22--44)%30 (16--45)%Progression/ relapse**33759038**1-year15 (5--29)%13 (7--22)%14 (7--21)%29 (16--44)%2-year25 (12--41)%16 (9--26)%19 (11--28)%29 (16--44)%3-year25 (12--41)%18 (10--28)%19 (11--28)%32 (18--48)%4-year25 (12--41)%18 (10--28)%21 (12--30)%32 (18--48)%PFS**33759038**1-year79 (63--91)%67 (56--77)%66 (56--76)%47 (32--63)%2-year62 (45--78)%54 (43--66)%56 (45--66)%41 (26--57)%3-year58 (41--75)%50 (38--62)%56 (45--66)%38 (23--54)%4-year58 (41--75)%45 (33--58)%47 (36--58)%38 (23--54)%Overall survival**33759038**1-year88 (75--97)%73 (63--83)%71 (61--80)%63 (47--78)%2-year78 (62--90)%62 (51--73)%59 (48--69)%52 (36--67)%3-year70 (52--85)%58 (46--70)%57 (47--68)%52 (36--67)%4-year70 (52--85)%54 (41--66)%50 (39--62)%52 (36--67)%*CR* complete response, *PR* partial response, *Prob* probability, *CI* confidence interval, *N* number, *NRM* non-relapse mortality, *PFS* progression-free survivalFig. 3Outcomes of AITL patients based on the disease status at allo-HCT. **a** Cumulative incidence of non-relapse mortality. **b** Cumulative incidence of lymphoma progression/relapse. **c** Progression-free survival. **d** Overall survival

Discussion {#Sec14}
==========

Prospective studies evaluating the outcomes of allo-HCT exclusively in AITL have not been performed given an overall rarity of this PTCL subtype. Here, we performed a registry analysis of AITL patients receiving first allo-HCT and made several important observations. First, allo-HCT provided durable disease control in patients with AITL as evidenced by 4-year PFS of 47%. Second, the risk of relapse tended to plateau at 2-year post allo-HCT. Lastly, allo-HCT provided durable disease control even in patients with a failed prior auto-HCT and those subjects with refractory disease at the time of allografting.

Auto-HCT has been previously studied as a consolidation modality for patients with AITL in first CR and beyond. While auto-HCT can provide durable disease control in AITL subjects in CR1, the outcomes of patients not in CR, or those with heavily pretreated disease are not optimal \[[@CR10]\]. In addition, despite low transplant-related mortality, the risk of relapse following autografting remains high (1- and 2-year relapse risk is 40% and 51%, respectively) \[[@CR10]\]. In contrast, allo-HCT provides excellent survival outcomes for patients with AITL with a lower risk of relapse. Additional file [1](#MOESM1){ref-type="media"}: Table S1 summarizes the retrospective studies (*n* ≥ 9) that have looked at the role of allo-HCT in AITL \[[@CR11], [@CR14]--[@CR16]\]. The current study is the largest registry validation of these results showing durable responses in patients with AITL following allo-HCT. Though previous studies included patients with prior auto-HCT failure and chemorefractory state, the data are limited by very small patient numbers (for example, the previously published study with a large number of AITL patients \[*n* = 45\] included 15 patients with prior auto-HCT failure and 18 patients with chemorefractory disease at allo-HCT) \[[@CR14]\] limiting the ability to draw meaningful conclusions. Considering the fact that ASBMT Clinical Practice Recommendation Panel \[[@CR23]\] endorses the use of auto-HCT in AITL patients in CR1/PR1, and the high rates of disease relapse in patients receiving high-dose therapy, addressing the role of a subsequent allo-HCT is a clinically important question. In the current analysis, we did not observe any statistically significant differences in outcomes for patients who had prior auto-HCT vs no prior auto-HCT. Our results support the curative potential of allo-HCT in high-risk AITL patients who have failed a prior auto-HCT.

Limited data are published on the role of allo-HCT in refractory AITL. Registry data from the European Society for Blood and Marrow Transplantation (EBMT) identified chemorefractory disease as a predictor of inferior outcomes but included only 18 refractory AITL patients \[[@CR14]\]. In the current analysis, the 4-year PFS and OS of chemorefractory patients was 38% and 52% respectively, which supports the use of allografting in this ultra-high-risk subset of patients (who otherwise are fit to undergo allo-HCT). In our study, we did not find a relationship between chronic GVHD and relapse rate in contrast to the previously reported data \[[@CR14]\]. The retrospective nature of the registry data does not permit us to analyze the optimal timing of allo-HCT. While the outcomes of CR1 patients in the current study were favorable (4-year PFS and OS 58% and 70%), prior studies have also suggested very encouraging outcomes of AITL patients undergoing auto-HCT in CR1 \[[@CR10], [@CR24]\].

AITL is a challenging diagnosis with roughly only 80% concordance even among expert pathologists with access to archival tissue \[[@CR3], [@CR7]\]. One of the limitations of the current study is the lack of central pathology review of archival tissue for all patients. The current study included cases as diagnosed by the pathologists at the respective institutions. Of note, disease histology is one of the critical fields CIBMTR examines during its onsite transplant center audits (where diagnosis reported to CIBMTR is audited relative to the pathology records available at the reporting center). In recent CIBMTR studies involving rare T-cell histologies, \> 95% concordance was seen between center-reported diagnosis and central review of pathology reports \[[@CR25], [@CR26]\]. We acknowledge that this analysis is not a substitute of central review of archival tissue by expert pathologists. At the same time, it is important to note that the majority of prospective clinical trials enrolling AITL subjects accept the patients based on the pathology reports at the participating sites, without a mandatory central review of archival tissue. In addition, the CIBMTR registry does not capture post-relapse salvage therapy, thereby limiting the ability to assess the post allo-HCT relapse survival.

Conclusions {#Sec15}
===========

With a better understanding of the biology and development of prognostic tools, there has been a major effort to study novel drug combinations and immunotherapy agents (including checkpoint inhibitors and chimeric antigen receptor T-cell \[CAR-T\] therapy) in patients with NHL. Brentuximab vedotin (anti-CD30 antibody-drug conjugate) is being studied in combination with chemotherapy in the frontline setting in PTCL patients (ECHELON 2 trial, NCT 01777152). The final results are eagerly awaited to assess the impact of CD30-directed therapies in the subset of AITL patients. While the data on CAR-T cell therapy for B-cell NHL (mainly diffuse large B-cell lymphoma) in the relapsed/refractory setting is impressive \[[@CR27]\], similar constructs in T-cell NHL have not been translated to the bedside. Our results suggest that allo-HCT offers the potential for cure in AITL patients including those with otherwise chemo-refractory disease. In the foreseeable future, allo-HCT is likely to remain an important therapeutic option for AITL patients.

Additional file
===============

 {#Sec16}

Additional file 1:**Table S1.** Outcomes of patients with AITL who underwent allogeneic HCT. **Table S2.** Variables tested in Cox proportional hazards regression models. **Table S3.** Causes of Death. **Table S4.** Conditioning Intensity. **Table S5.** Details of GVHD prophylaxis regimens. **Table S6.** Univariate outcomes of AITL patients receiving alternative donor sources. (DOCX 29 kb)
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